News Corporation Class A Common Stock vs 10X Genomics Inc — how do they compare? News Corporation Class A Common Stock trades at $29.06 (market cap $16.14B), while 10X Genomics Inc trades at $82 (market cap $10.07B). The key difference: News Corporation Class A Common Stock is the larger of the two by market cap, and News Corporation Class A Common Stock pays a 0.69% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold News Corporation Class A Common Stock for 0 Days and 10X Genomics Inc for 92 Days on average.
| NWSA | TXG | |
|---|---|---|
Market Cap | $16.14B | $10.07B |
Volume | 4,310,610 | 5,657,286 |
Sector | Media | Health |
52-Week High | $31.19 | $97.74 |
52-Week Low | $22.40 | $11.48 |
Typical Hold Time | 0 Days | 92 Days |
Enterprise Value | $16.96B | $9.59B |
Dividend Yield | 0.69% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
News Corporation operates businesses in news and information services, digital real estate, and book publishing. Its brands include Dow Jones, The Wall Street Journal, HarperCollins, Realtor.com, and realestate.com.au.
Read more on NWSA →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →